https://pharmaphorum.com/r-d/breaking-into-the-global-pharmaceutical-market-rudacure/
RudaCure is a four-year-old entreprise biotechnologienologique based in the Corée du Sud, focusing on ocular disease and douleur chronique with a pair of potentially first-in-class drugs. L'entreprise récemment raised $16.5 million in Series A funding and has partnered with Hanlim Pharmaceuticals, a local pharma company, to develop and distribute its candidat-médicament for Sécheresse oculaire.
L'entreprise récemment incorporated in the US and is participating in a MassChallenge accelerator programme via a partenariat between MassChallenge, Korea’s Bio I-Corps programme and the Korean Innovation Center in Washington. They’ve also begun attending US-based events like JP Morgan, to start to make the connections that will help them sell and develop their products on a global scale.
